U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.» Read More
NEW YORK, Aug 13- U.S. stocks ended higher on Wednesday, with the Dow Jones industrial average returning to positive territory for the year, as surging biotech shares helped investors shrug off disappointing retail sales data.
Macy's Inc quarterly earnings missed analysts' estimates and the department store operator slashed its full-year same-store sales forecast, driving the stock down 5.5 percent to $56.47. Other major retailers, including Wal-Mart Stores Inc, are expected to report results on Thursday. Wal-Mart shares slipped 0.3 percent to $74.03.
NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.
Aug 13- Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion.
Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..
NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
*S&P 500 pulls back after hitting intraday record. NEW YORK, June 24- U.S. stocks fell on Tuesday as early enthusiasm from economic data faded and concerns about the violence in Iraq gave investors a reason to sell and book some profits, driving the Dow to its biggest drop in over a month. On Tuesday, the Dow suffered its biggest drop since May 20.
Check out which companies are making headlines after the bell Tuesday.
Stocks fell, with the S&P 500 turning lower after rising to another record.
Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.
NEW YORK, June 24- U.S. stocks turned lower on Tuesday after stronger-than-expected data lifted them to a fresh record earlier in the day, while the sterling tumbled after the Bank of England governor said spare capacity would need to be used up before a rate rise is needed.
*S&P 500 pulls back a bit after hitting intraday record. NEW YORK, June 24- U.S. stocks mostly slipped on Tuesday as earlier gains from economic data faded, but the Nasdaq advanced as a result of gains in biotech shares.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
*S&P 500 hits intraday record, continues recent strength. NEW YORK, June 24- U.S. stocks rose on Tuesday, boosted by some strong data while the Nasdaq outperformed thanks to gains in technology and biotech shares. Consumer confidence hit its highest level since January 2008 in June, while new home sales jumped 18.6 percent to a six-year high in May.
Take a look at some of Tuesday's midday movers.
*Consumer confidence at highest since Jan 2008. NEW YORK, June 24- U.S. stocks were little changed on Tuesday as some strong data wasn't enough to solidly lift indexes in the wake of a recent rally, though the Nasdaq index was boosted by gains in technology and biotech shares.
NEW YORK, June 24- U.S. stock index futures pointed to a flat open on Tuesday, suggesting investors continued to search for direction following a sharp rally that took indexes to records last week.
June 24- A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco and its experimental lumacaftor succeeded in improving lung function in a pair of closely watched late-stage trials of patients with the most common genetic mutation associated with the rare lung disease.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.